
1. mbio. 2016 jul 5;7(4). pii: e00696-16. doi: 10.1128/mbio.00696-16.

mutations plasmodium falciparum cyclic amine resistance locus (pfcarl)
confer multidrug resistance.

lamonte g(1), lim my(2), wree m(1), reimer c(1), nachon m(1), corey v(1), gedeck 
p(3), plouffe d(4), du a(1), figueroa n(1), yeung b(3), bifani p(5), winzeler
ea(1).

author information: 
(1)department pediatrics, school medicine, university california san
diego, la jolla, california, usa.
(2)novartis institute tropical diseases, singapore, singapore national
university singapore, singapore.
(3)novartis institute tropical diseases, singapore, singapore.
(4)genomics institute novartis research foundation, san diego, california,
usa.
(5)novartis institute tropical diseases, singapore, singapore national
university singapore, singapore genomics institute novartis research
foundation, san diego, california, usa pablo.bifani@novartis.com.

mutations plasmodium falciparum cyclic amine resistance locus (pfcarl) are
associated parasite resistance imidazolopiperazines, potent class
of novel antimalarial compounds display prophylactic and
transmission-blocking activity, addition activity blood-stage
parasites. here, show pfcarl encodes protein, predicted
molecular weight 153 kda, localizes cis-golgi apparatus the
parasite asexual sexual blood stages. utilizing clustered regularly
interspaced short palindromic repeat (crispr)-mediated gene introduction 5
variants (l830v, s1076n/i, v1103l, i1139k), demonstrate mutations 
pfcarl sufficient generate resistance imidazolopiperazines 
both asexual sexual blood-stage parasites. determined the
mutant pfcarl protein confers resistance several structurally unrelated
compounds. data suggest pfcarl modulates levels small-molecule 
inhibitors affect golgi-related processes, protein sorting or
membrane trafficking, therefore important mechanism resistance in
malaria parasites.importance: several previous vitro evolution studies have
implicated plasmodium falciparum cyclic amine resistance locus (pfcarl) 
potential target imidazolopiperazines, potent antimalarial compounds with
broad activity different parasite life cycle stages. given the
imidazolopiperazines currently tested clinical trials, understanding
their mechanism resistance cellular processes involved allow more
effective clinical usage.

copyright © 2016 lamonte et al.

doi: 10.1128/mbio.00696-16 
pmcid: pmc4958248
pmid: 27381290  [indexed medline]

